Forest Services
Introduction: Keytruda’s Role in Cancer Immunotherapy
Keytruda (Pembrolizumab) is a monoclonal antibody approved by the US FDA in 2014 under accelerated approval for melanoma treatment, later extended to multiple cancers including non-small cell lung cancer (NSCLC). In India, the Central Drugs Standard Control Organization (CDSCO) approved Keytruda in 2017 for NSCLC. It functions as an immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor on T-cells, blocking interaction with PD-L1 and PD-L2 ligands on tumor cells, thereby restoring T-cell mediated immune response against cancer cells. This mechanism has improved 5-year survival rates by 20-30% in NSCLC patients compared to chemotherapy (New England Journal of Medicine, 2022). However, the rise of counterfeit Keytruda threatens treatment efficacy and patient safety, necessitating regulatory vigilance.
UPSC Relevance
- GS Paper 2: Health Sector, Drug Regulation, Patient Safety
- GS Paper 3: Science and Technology in Health, Biotechnology, Economic Impact of Healthcare
- Essay: Challenges of Drug Counterfeiting and Health Infrastructure
Mechanism of Action: How Keytruda Enhances Immune Response
Keytruda is a humanized IgG4 monoclonal antibody that selectively binds to the PD-1 receptor on activated T-cells. Tumors exploit the PD-1/PD-L1 pathway to evade immune detection by inactivating cytotoxic T-cells. By blocking PD-1, Keytruda prevents this immune checkpoint interaction, reactivating T-cell cytotoxicity against tumor cells. This contrasts with traditional chemotherapy that directly kills rapidly dividing cells but with broader cytotoxic effects.
- Targets PD-1 receptor to inhibit immune checkpoint signaling
- Restores T-cell mediated apoptosis of tumor cells
- Approved for multiple cancers including melanoma, NSCLC, head and neck squamous cell carcinoma
- Improves long-term survival and reduces tumor progression
Legal Framework Governing Drug Approval and Counterfeit Control in India
The Drugs and Cosmetics Act, 1940 and its Rules (1945) provide the primary legal framework for drug approval, manufacture, and sale in India. Sections 18, 27, and 27A explicitly prohibit manufacture and sale of spurious or counterfeit drugs. Rule 122-E mandates stringent quality control for oncology drugs, including biologics like Keytruda. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 regulates misleading claims that can exacerbate counterfeit drug consumption. The Clinical Establishments (Registration and Regulation) Act, 2010 ensures healthcare providers maintain standards, indirectly controlling drug dispensation. The Supreme Court in Union of India v. Mohd. Rafique (2018) underscored the State’s duty to ensure drug quality and patient safety, reinforcing regulatory enforcement.
- Drugs and Cosmetics Act, 1940: Sections 18, 27, 27A target spurious drugs
- Drugs and Cosmetics Rules, 1945: Rule 122-E mandates oncology drug quality
- Drugs and Magic Remedies Act, 1954: Controls misleading drug advertisements
- Clinical Establishments Act, 2010: Regulates healthcare delivery standards
- Supreme Court rulings emphasize patient safety and drug quality enforcement
Economic Dimensions: Market Size, Pricing, and Counterfeit Impact
The global immunotherapy market was valued at approximately USD 85 billion in 2023, with Keytruda commanding around 30% market share (IQVIA, 2024). India’s oncology drug market is projected to grow at a CAGR of 12% until 2027 (Frost & Sullivan, 2023). The government allocated INR 6,000 crore for cancer treatment under the National Cancer Control Programme (NCCP) in 2023-24. Keytruda’s branded price in India is roughly INR 3,00,000 per dose, making it prohibitively expensive for many patients. Counterfeit versions, priced 40-60% lower, flood the market, causing estimated economic losses of USD 200 million annually (WHO, 2023) and posing severe health risks due to compromised efficacy and safety.
- Global immunotherapy market: USD 85 billion (2023), Keytruda ~30% share
- India oncology drug market CAGR: 12% till 2027
- Government cancer treatment budget: INR 6,000 crore (2023-24)
- Keytruda price in India: ~INR 3,00,000/dose; counterfeit 40-60% cheaper
- Counterfeit oncology drugs cause USD 200 million annual losses in India
Institutional Roles in Regulating and Monitoring Keytruda
CDSCO is the apex regulatory body responsible for drug approvals and quality control in India, including biologics like Keytruda. The National Pharmaceutical Pricing Authority (NPPA) regulates pricing of essential medicines, though Keytruda falls outside price caps due to its patented biologic status. The Indian Council of Medical Research (ICMR) conducts clinical research and surveillance on cancer therapies. The World Health Organization (WHO) provides global guidelines on counterfeit drug detection and pharmacovigilance. The National Cancer Control Programme (NCCP) coordinates cancer prevention and treatment strategies nationally. The US FDA serves as a regulatory benchmark, with its track-and-trace systems reducing counterfeit oncology drugs by over 70% from 2015-2022.
- CDSCO: Drug approval and quality control
- NPPA: Pricing regulation of essential drugs
- ICMR: Cancer research and clinical trials
- WHO: Guidelines on counterfeit drug detection
- NCCP: National cancer treatment coordination
- FDA (USA): Benchmark for immunotherapy regulation and supply chain security
Counterfeit Keytruda: Identification and Risks
Counterfeit Keytruda often mimics packaging and labeling but lacks the biologic integrity of the genuine monoclonal antibody, leading to therapeutic failure or adverse reactions. Detection requires advanced analytical techniques, including mass spectrometry and immunoassays, which are not widely accessible in India. Counterfeit drugs constitute 10-15% of the oncology market in some Indian regions (WHO, 2023). Public awareness campaigns increased by 35% post-2022 following government advisories, yet gaps remain in supply chain security and patient education.
- Counterfeits mimic packaging but lack active biologic components
- Advanced lab tests needed for authentication, limited access in India
- 10-15% market share of counterfeit oncology drugs in some regions
- Public awareness campaigns up 35% after 2022 government advisories
- Supply chain vulnerabilities exploited by counterfeiters
Comparative Analysis: India vs. USA Regulatory Approaches
| Parameter | India | USA |
|---|---|---|
| Regulatory Authority | CDSCO | FDA |
| Track-and-Trace System | Absent for biologics like Keytruda | Implemented under Drug Supply Chain Security Act (2013) |
| Counterfeit Oncology Drug Reduction (2015-2022) | Limited data; counterfeit share 10-15% regionally | Reduced by >70% |
| Pricing Regulation | NPPA regulates generics; biologics largely unregulated | Market-driven; insurance and Medicare influence pricing |
| Public Awareness | Increasing but uneven | Systematic and widespread campaigns |
Significance and Way Forward
- Implement a national track-and-trace system specifically for biologics to secure the supply chain and prevent counterfeit infiltration.
- Strengthen laboratory infrastructure for advanced biologic drug authentication across states.
- Enhance inter-agency coordination between CDSCO, NPPA, and law enforcement to prosecute counterfeiters swiftly.
- Expand public awareness campaigns targeting patients and healthcare providers about risks of counterfeit immunotherapy drugs.
- Incorporate stricter provisions under the Drugs and Cosmetics Act to address biologic-specific counterfeit challenges.
- Keytruda blocks the PD-L1 receptor on tumor cells to activate T-cells.
- Keytruda was first approved by the US FDA in 2014 for melanoma treatment.
- Keytruda is a traditional chemotherapy drug targeting rapidly dividing cells.
Which of the above statements is/are correct?
- Counterfeit oncology drugs constitute less than 1% of the Indian market.
- The Drugs and Cosmetics Act, 1940 prohibits manufacture and sale of spurious drugs.
- India currently has a comprehensive track-and-trace system for biologics like Keytruda.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 (Health and Social Issues), Paper 3 (Science and Technology in Health)
- Jharkhand Angle: Rising cancer incidence in Jharkhand with limited access to advanced immunotherapy drugs like Keytruda; prevalence of counterfeit drugs in rural healthcare settings.
- Mains Pointer: Highlight state-level challenges in drug quality control, importance of regulatory enforcement, and need for awareness campaigns in Jharkhand.
What is the primary mechanism by which Keytruda works?
Keytruda blocks the PD-1 receptor on activated T-cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells, thereby restoring T-cell immune response against cancer cells.
When was Keytruda approved in India and for which cancer?
Keytruda was approved by the CDSCO in 2017 for treatment of non-small cell lung cancer (NSCLC).
Which legal provisions govern counterfeit drug regulation in India?
The Drugs and Cosmetics Act, 1940 (Sections 18, 27, 27A) prohibits manufacture and sale of spurious drugs; the Drugs and Cosmetics Rules, 1945 (Rule 122-E) mandates quality control for oncology drugs.
What economic impact do counterfeit oncology drugs have in India?
Counterfeit oncology drugs cause estimated economic losses of USD 200 million annually in India and pose risks of treatment failure and adverse health outcomes.
How does the US FDA’s approach to counterfeit oncology drugs differ from India’s?
The US FDA enforces a track-and-trace system under the Drug Supply Chain Security Act (2013), reducing counterfeit oncology drugs by over 70% between 2015-2022, while India lacks a similar system for biologics like Keytruda.